NCT02777242View on ClinicalTrials.gov

Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Hypogonadism
Interventions
COMBINATION_PRODUCT

Testosterone enanthate auto-injector

SC injections of QST 50 mg or 75 mg or 100 mg

Trial Locations (3)

10016

New York

35235

Birmingham

43213

Columbus

Sponsors
All Listed Sponsors
lead

Antares Pharma Inc.

INDUSTRY

NCT02777242 - Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism | Biotech Hunter | Biotech Hunter